- AstraZeneca completed studies for transitioning Breztri to a next-gen propellant with 99.9% lower Global Warming Potential.
Mon Sep 09 05:02:40 -0000 2024 UTC–AstraZeneca has made an important change to one of its inhalers, Breztri, used for treating COPD (a lung condition), by switching to a new, environmentally friendly propellant. This new propellant has almost no impact on global warming, making it much better for the environment compared to the older type.
Same Effective Treatment
This means that you can still get the same effective treatment for COPD, but now with a much smaller carbon footprint. It’s a positive step towards making healthcare more sustainable, showing that companies can help protect the planet while still providing essential medical care. This move might encourage other pharmaceutical companies to adopt similar eco-friendly practices in their products.
Reduction in Global Warming Potential
The new propellant, HFO-1234ze, boasts a 99.9% reduction in global warming potential (GWP) compared to the previous hydrofluoroalkane (HFA) propellants traditionally used in metered-dose inhalers. This move aligns with AstraZeneca’s broader commitment to sustainability and reducing the carbon footprint of its products.
Chronic Obstructive Pulmonary Disease (COPD)
Breztri is a maintenance treatment for chronic obstructive pulmonary disease (COPD), and the switch to this eco-friendly propellant represents a significant advancement in making inhalation therapies more environmentally responsible. The next-generation propellant is designed to maintain the effectiveness and reliability of the medication while drastically reducing its impact on global warming.
Greener Pharma
This transition is part of a growing trend in the pharmaceutical industry to develop greener alternatives in medication delivery systems, particularly in respiratory treatments, where traditional propellants have been a notable contributor to greenhouse gas emissions. AstraZeneca’s initiative with Breztri could set a precedent for other companies to follow suit in their efforts to mitigate the environmental impact of essential medicines.